骨粗鬆症治療薬市場-世界の産業規模、シェア、動向、機会、予測、投与経路別、薬剤タイプ別、地域別、競合別、2020～2030年

骨粗鬆症治療薬の世界市場は、2024年に134億米ドルと評価され、2030年には169億1,000万米ドルに達し、CAGR 4.15％で成長すると予測されています。

骨粗鬆症は、骨量の低下と骨折リスクの高まりを特徴とする進行性の骨格障害であり、主に閉経後の女性と高齢者が罹患します。世界の平均寿命が延びるにつれて、骨粗鬆症とそれに伴う骨折の有病率も上昇し、薬理療法に対する強い需要を牽引しています。

同市場は、ビスフォスフォネート、SERM、RANKリガンド阻害剤、カルシトニン、副甲状腺ホルモンアナログなど、さまざまな薬剤カテゴリーにまたがっています。アレンドロネートやリセドロネートなどのビスフォスフォネート系薬剤は、その手頃な価格と広く臨床使用されていることから、歴史的に優位を占めてきました。市場の展望は依然として良好であるが、新しい生物製剤による治療に伴う高額な費用、長期にわたる副作用への懸念、アドヒアランスの問題などの課題が、より広範な採用を阻害し続けています。

主要市場促進要因

ヘルスケア産業の成長

主要市場課題

治療費の高騰

主要市場動向

在宅骨粗鬆症治療薬の増加

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 COVID-19が世界の骨粗鬆症治療薬市場に与える影響

第5章 世界の骨粗鬆症治療薬市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 投与経路別（経口、注射、その他）
  • 薬剤タイプ別（副甲状腺ホルモン療法、ビスフォスフォネート、カルシトニン、選択的エストロゲン受容体モジュレーター、その他）
  • 地域別
  • 企業別（2024年）
• 市場マップ

第6章 北米の骨粗鬆症治療薬市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • メキシコ
  • カナダ

第7章 欧州の骨粗鬆症治療薬市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • フランス
  • ドイツ
  • 英国
  • イタリア
  • スペイン

第8章 アジア太平洋の骨粗鬆症治療薬市場展望

• 市場規模・予測
• 市場シェア・予測
• アジア太平洋：国別分析
  • 中国
  • インド
  • 韓国
  • 日本
  • オーストラリア

第9章 南米の骨粗鬆症治療薬市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカの骨粗鬆症治療薬市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 合併と買収
• 製品上市

第13章 混乱：紛争、パンデミック、貿易障壁

第14章 世界の骨粗鬆症治療薬市場：SWOT分析

第15章 ポーターのファイブフォース分析

• 産業内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第16章 競合情勢

• Eli Lilly and Company
• Pfizer Inc.
• F. Hoffmann-La Roche Ltd
• Teva Pharmaceutical Industries Ltd.
• GlaxoSmithKline plc.
• Novartis International AG
• Merck & Co. Inc.
• Amgen Inc.
• Radius Health Inc.
• Actavis PLC

第17章 戦略的提言

第18章 調査会社について・免責事項

The Global Osteoporosis Drugs Market was valued at USD 13.40 Billion in 2024 and is projected to reach USD 16.91 Billion by 2030, growing at a CAGR of 4.15%. Osteoporosis, a progressive skeletal disorder marked by low bone mass and heightened fracture risk, predominantly affects postmenopausal women and the elderly. As global life expectancy rises, so too does the prevalence of osteoporosis and associated fractures, driving strong demand for pharmacological therapies.

The market spans various drug categories, including bisphosphonates, SERMs, RANK ligand inhibitors, calcitonin, and parathyroid hormone analogs. Bisphosphonates, such as alendronate and risedronate, have historically dominated due to their affordability and widespread clinical use. While the market outlook remains favorable, challenges such as high costs associated with newer biologic treatments, concerns regarding long-term side effects, and adherence issues continue to temper broader adoption.

Key Market Drivers

Growth in Healthcare Industry

The global healthcare sector's continued growth plays a pivotal role in advancing the osteoporosis drugs market. With annual sales surpassing USD 4 trillion, key healthcare segments include pharmaceuticals and biotechnology, generating nearly USD 850 billion, and medical diagnostics and technology, contributing over USD 400 billion. As healthcare infrastructure expands and access improves worldwide, there is a heightened focus on early detection and effective treatment of chronic age-related conditions like osteoporosis. This rising awareness and investment are translating into increased demand for medications aimed at enhancing bone density and minimizing fracture risk.

Key Market Challenges

High Cost of Therapy

The substantial cost of osteoporosis therapy presents a major barrier to widespread access, particularly in lower-income and underinsured populations. Although biologics such as denosumab and parathyroid hormone analogs like teriparatide offer strong efficacy for high-risk patients, these treatments are priced significantly higher than conventional options like bisphosphonates. This pricing disparity limits affordability, especially in regions where public healthcare systems are underfunded or health insurance coverage is insufficient. The long-term nature of osteoporosis treatment further intensifies the economic burden for patients and providers alike.

Key Market Trends

Rise in Home-Based Osteoporosis Care

The growing shift toward home-based osteoporosis management is reshaping the landscape of care delivery. In May 2023, the International Osteoporosis Foundation (IOF) launched the Build Better Bones platform-a digital resource designed to support individuals and caregivers with practical tools for strengthening bones and preventing fragility fractures. This trend reflects a broader move toward patient-centric care models, particularly for elderly or mobility-limited patients.

By facilitating remote education, personalized exercise routines, and nutritional guidance, home-based care helps improve adherence to long-term drug regimens and enhances clinical outcomes. It also reduces pressure on healthcare facilities, offering a more accessible and cost-effective approach to chronic disease management.

Key Market Players

• Eli Lilly and Company
• Pfizer Inc.
• F. Hoffmann-La Roche Ltd
• Teva Pharmaceutical Industries Ltd.
• GlaxoSmithKline plc.
• Novartis International AG
• Merck & Co. Inc.
• Amgen Inc.
• Radius Health Inc.
• Actavis PLC

Report Scope

In this report, the Global Osteoporosis Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Osteoporosis Drugs Market, By Route of Administration:

• Oral
• Injectables
• Others

Osteoporosis Drugs Market, By Drug Type:

• Parathyroid Hormone Therapy
• Bisphosphonates
• Calcitonin
• Selective Estrogen Receptor Modulators
• Others

Osteoporosis Drugs Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Osteoporosis Drugs Market.

Available Customizations

Global Osteoporosis Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, and Trends

4. Impact of COVID-19 on Global Osteoporosis Drugs Market

5. Global Osteoporosis Drugs Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Route of Administration (Oral, Injectables, Others)
  • 5.2.2. By Drug Type (Parathyroid Hormone Therapy, Bisphosphonates, Calcitonin, Selective Estrogen Receptor Modulators, Others)
  • 5.2.3. By Region
  • 5.2.4. By Company (2024)
• 5.3. Market Map

6. North America Osteoporosis Drugs Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Route of Administration
  • 6.2.2. By Drug Type
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Osteoporosis Drugs Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Route of Administration
      • 6.3.1.2.2. By Drug Type
  • 6.3.2. Mexico Osteoporosis Drugs Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Route of Administration
      • 6.3.2.2.2. By Drug Type
  • 6.3.3. Canada Osteoporosis Drugs Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Route of Administration
      • 6.3.3.2.2. By Drug Type

7. Europe Osteoporosis Drugs Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Route of Administration
  • 7.2.2. By Drug Type
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Osteoporosis Drugs Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Route of Administration
      • 7.3.1.2.2. By Drug Type
  • 7.3.2. Germany Osteoporosis Drugs Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Route of Administration
      • 7.3.2.2.2. By Drug Type
  • 7.3.3. United Kingdom Osteoporosis Drugs Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Route of Administration
      • 7.3.3.2.2. By Drug Type
  • 7.3.4. Italy Osteoporosis Drugs Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Route of Administration
      • 7.3.4.2.2. By Drug Type
  • 7.3.5. Spain Osteoporosis Drugs Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Route of Administration
      • 7.3.5.2.2. By Drug Type

8. Asia Pacific Osteoporosis Drugs Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Route of Administration
  • 8.2.2. By Drug Type
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Osteoporosis Drugs Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Route of Administration
      • 8.3.1.2.2. By Drug Type
  • 8.3.2. India Osteoporosis Drugs Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Route of Administration
      • 8.3.2.2.2. By Drug Type
  • 8.3.3. South Korea Osteoporosis Drugs Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Route of Administration
      • 8.3.3.2.2. By Drug Type
  • 8.3.4. Japan Osteoporosis Drugs Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Route of Administration
      • 8.3.4.2.2. By Drug Type
  • 8.3.5. Australia Osteoporosis Drugs Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Route of Administration
      • 8.3.5.2.2. By Drug Type

9. South America Osteoporosis Drugs Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Route of Administration
  • 9.2.2. By Drug Type
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Osteoporosis Drugs Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Route of Administration
      • 9.3.1.2.2. By Drug Type
  • 9.3.2. Argentina Osteoporosis Drugs Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Route of Administration
      • 9.3.2.2.2. By Drug Type
  • 9.3.3. Colombia Osteoporosis Drugs Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Route of Administration
      • 9.3.3.2.2. By Drug Type

10. Middle East and Africa Osteoporosis Drugs Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Route of Administration
  • 10.2.2. By Drug Type
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Osteoporosis Drugs Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Route of Administration
      • 10.3.1.2.2. By Drug Type
  • 10.3.2. Saudi Arabia Osteoporosis Drugs Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Route of Administration
      • 10.3.2.2.2. By Drug Type
  • 10.3.3. UAE Osteoporosis Drugs Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Route of Administration
      • 10.3.3.2.2. By Drug Type

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Disruptions : Conflicts, Pandemics and Trade Barriers

14. Global Osteoporosis Drugs Market: SWOT Analysis

15. Porters Five Forces Analysis

• 15.1. Competition in the Industry
• 15.2. Potential of New Entrants
• 15.3. Power of Suppliers
• 15.4. Power of Customers
• 15.5. Threat of Substitute Products

16. Competitive Landscape

• 16.1. Eli Lilly and Company
  • 16.1.1. Business Overview
  • 16.1.2. Company Snapshot
  • 16.1.3. Products & Services
  • 16.1.4. Financials (As Reported)
  • 16.1.5. Recent Developments
  • 16.1.6. Key Personnel Details
  • 16.1.7. SWOT Analysis
• 16.2. Pfizer Inc.
• 16.3. F. Hoffmann-La Roche Ltd
• 16.4. Teva Pharmaceutical Industries Ltd.
• 16.5. GlaxoSmithKline plc.
• 16.6. Novartis International AG
• 16.7. Merck & Co. Inc.
• 16.8. Amgen Inc.
• 16.9. Radius Health Inc.
• 16.10. Actavis PLC

17. Strategic Recommendations

18. About Us & Disclaimer